Potential first-in-class

Discover the landscape of Potential first-in-class in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Potential first-in-class, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

NMPA Approves Lilly's Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China
CompanyDrug

NMPA Approves Lilly’s Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China

Eli Lilly and Company (NYSE: LLY) announced that China's National Medical Products Administration (NMPA) has officially approved a new indication for its non‑covalent (reversible) BTK inhibitor Jaypirca (pirtobrutinib), as a…

Sino Biopharmaceutical's CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology

Sino Biopharmaceutical’s CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology

Sinovac and Egypt's GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase

Sinovac and Egypt’s GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

ImmuneOnco’s IMM2902 Receives FDA Fast-Track Designation for CD47/HER2 Targeting

CompanyDrug

Zai Lab’s Efgartigimod NDA Accepted by NMPA for Myasthenia Gravis

CompanyDrug

MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors

CompanyDrug

PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy

CompanyDeals

Henlius and Palleon Partner on HER2-Targeted Antibody-Sialidase Fusion Protein

CompanyDrug

Cosunter Pharma’s HBV Surface Antigen Inhibitor GST-HG121 Approved for Phase I Trial

CompanyDrug

Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors

CompanyDrug

Sichuan Kelun’s KL340399 Wins NMPA Approval for Solid Tumor Trials

Show More